Study flow diagram of patients with MDR TB in Georgia, 2009–2011.

<p>Study flow diagram of patients with MDR TB in Georgia, 2009–2011.</p

Bivariate and multivariable analyses of patient characteristics associated with cumulative risk of poor treatment outcome among adult pulmonary MDR-TB patients in Georgia 2009–2011.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094890#pone-0094890-t004" target="_blank"><u>Table 4</u></a><u>. Abbreviations</u>: MDR-multidrug-resistant; cRR-crude risk ratio; aRR-adjusted risk ratio; AFB-acid fast bacilli; <b>Bold</b> indicates statistically significant, two sided p-value <0.05.</p>A<p>Poor treatment outcome was defined as failed, defaulted, died, or transferred.</p>B<p>Variables in the adjusted model included all those with reported aRR estimates except <i>Failure to convert culture</i>.</p>C<p>Missing values were coded as no, none, or negative.</p>D<p>All patients were pulmonary, extra-pulmonary includes those with both pulmonary and extra-pulmonary TB.</p>E<p>Adjusted estimate obtained from a separate model for aRR due to 60 patients with treatment outcome who were missing culture conversion status.</p>F<p>Categories created by tertiles of conversion time.</p

Performance parameters of MTBDR<i>plus</i> in detecting INH R^∧, RIF R^∧, and MDR^∧ compared to conventional DST (reference standard)^#.

#<p>Values are percentages with 95% confidence interval in parentheses.</p><p>*PPV = positive predictive value, NPV = negative predictive value.</p>∧<p>INH R = isoniazid resistance, RIF R = rifampin resistance, MDR = multidrug resistance.</p

Diabetes mellitus and baseline characteristics of adult pulmonary MDR-TB patients in Georgia 2009–2012.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094890#pone-0094890-t001" target="_blank"><u>Table 1</u></a><u> Abbreviations</u>: RBG-random blood glucose; MDR-multidrug-resistant; STD-standard deviation; IQR-interquartile range; AFB-acid fast bacilli.</p>A<p>Based on medical records or self-reported by MDR-TB patients.</p>B<p>Statistically significant, two-sided p-value <0.05.</p>C<p>Variables with missing >5% among patients were reported in the table as a separate category but not calculated within the frequency distribution.</p>D<p>All patients had pulmonary MDR-TB; extra-pulmonary/disseminated includes those with both pulmonary and extra-pulmonary/disseminated.</p

Bivariate and multivariable hazard rate ratios for patient characteristics associated with sputum culture conversion among patients with MDR-TB in Georgia, 2009–2011.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0094890#pone-0094890-t002" target="_blank"><u>Table 2</u></a><u> Abbreviations</u>: IQR-interquartile range; MDR-multidrug-resistant; cHR-crude hazard rate ratio; aHR-adjusted hazard rate ratio; RBG-random blood glucose; AFB-acid fast bacilli; Neg-negative; Dissem-disseminated TB; <b>Bold</b> indicates statistically significant, two sided p-value <0.05.</p>A<p>Among patients who converted, median time (days) from MDR TB treatment initiation until first of two consecutive negative sputum cultures ≥30 days apart among patients.</p>B<p>The adjusted model included all variables with estimates in the aHR column.</p>C<p>Any resistance to a second-line TB drug.</p>D<p>Violated proportional hazards assumptions and not included in adjusted model.</p>E<p>Missing data for this variable was recoded into no/null category.</p>F<p>All patients were pulmonary, extra-pulmonary includes those with both pulmonary and extra-pulmonary TB.</p

Pattern of genetic mutations in phenotypic drug-resistant <i>Mycobacterium tuberculosis</i> isolates using the Genotype MTBDRplus assay.

<p>*Definitions of abbreviations: INH = isoniazid; RIF = rifampicin; MDR = multidrug-resistant.</p>∧<p>Values are numbers, with percentages in parentheses.</p

Distribution of MTBDR<i>plus</i> assay results according to phenotypic drug resistance patterns using conventional drug susceptibility testing for specimens with both valid culture and MTBDRplus assay results.

<p>Distribution of MTBDR<i>plus</i> assay results according to phenotypic drug resistance patterns using conventional drug susceptibility testing for specimens with both valid culture and MTBDRplus assay results.</p

Average time to results in days for detection of TB and associated drug resistance (N = 458)^*.

<p>*Values are average number of days with one standard deviation in parentheses.</p>∧<p>DST = drug susceptibility testing.</p

Sputum culture results for all AFB smear positive tuberculosis suspects and corresponding complete MTBDRplus assay results.

<p>Sputum culture results for all AFB smear positive tuberculosis suspects and corresponding complete MTBDRplus assay results.</p